About Lungpacer
Lungpacer is a company based in Vancouver (Canada) founded in 2009. Lungpacer has raised $121.38 million across 8 funding rounds from investors including Canadian Institutes of Health Research and Military Health. Lungpacer offers products and services including AeroPace System and AeroNova System. Lungpacer operates in a competitive market with competitors including Belluscura, hemovent, ALung, OneBreath and Securisyn, among others.
- Headquarter Vancouver, Canada
- SectorsHealthcare
- Website lungpacer.com
- Social LinkedIn X YouTube
- Legal Name Lungpacer Medical, Inc.
- Total Equity Funding$121.38M (USD)
in 8 rounds
- Investors
Products & Services of Lungpacer
Lungpacer offers a comprehensive portfolio of products and services, including AeroPace System and AeroNova System.
Stimulates diaphragm to aid weaning from mechanical ventilation.
Used for clinical investigations in breathing support technologies.
Apps and channels of Lungpacer
its YouTube channel Lungpacer Medical Inc. has 144 subscribers and 8 videos.
Videos from Lungpacer
The most watched videos on Lungpacer's YouTube channel, Lungpacer Medical Inc. (144 subscribers). Click a video to play it here.
More on Lungpacer Medical Inc..
Funding Insights of Lungpacer
Lungpacer has successfully raised a total of $121.38M across 8 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $121.38M
- Total Rounds 8
- First Round $155,848
(Mar 2013)
- Investors Count 2
All 8 funding rounds of Lungpacer with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2026 | $12M | Series B | – | – | – |
| Mar 2025 | $10M | Series B | – | – | – |
| Apr 2022 | $20M | Series B | – | – | – |
| Jan 2021 | $5.36M | Grant | – | – | |
| Jan 2021 | $16M | Series B | – | – | – |
| May 2019 | $55.76M | Series B | – | – | – |
| Jun 2017 | $19.62M | Series A | – | – | – |
| Mar 2013 | $155,848 | Grant | – | – |
2 investors in total: 2 institutional.
Investors in Lungpacer
Lungpacer has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Canadian Institutes of Health Research and Military Health.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Administers health care and support for military personnel and operations. | – | health.mil | Falls Church, United States | |
Health research projects in Canada are funded and supported. | 2000 | cihr-irsc.gc.ca | Ottawa, Canada |
Investor details for Lungpacer
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Lungpacer
41 people are tracked at Lungpacer (11 in leadership, 17 in board & advisors, 13 in team).
| Name | Role | Group |
|---|---|---|
Doug Evans | CEO | Leadership |
Judy Ways | VP, Regulatory Affairs | Leadership |
Eric N. Folk | Director of Engineering | Leadership |
Chris Watt | Quality Director | Leadership |
Scott Mitman | Director Of Mechanical Engineering | Leadership |
Andrew Ganton | Vice President Of Marketing | Leadership |
Viral Thakkar | VP, Operations | Leadership |
Rosemarie Dhavale | VP, Finance | Leadership |
Megan O'Toole | Director Clinical Operations | Leadership |
Ravi Khatri | Director Of Regulatory Affairs | Leadership |
Mike Longo | VP Of Engineering At Lungpacer Medical | Leadership |
Joshua O. Benditt | Clinical Board Member | Board & advisors |
Rich Branson | Clinical Board Member | Board & advisors |
Ralf Ewert | Clinical Board Member | Board & advisors |
Dean Hess | Clinical Board Member | Board & advisors |
François Lellouche | Clinical Board Member | Board & advisors |
Nicholas S. Hill | Clinical Board Member | Board & advisors |
Martin Dres | Clinical Board Member | Board & advisors |
Dimitris Georgopoulos | Clinical Board Member | Board & advisors |
Robert C. Hyzy | Clinical Board Member | Board & advisors |
21 more people are available in the full profile.
Complete people profiles for Lungpacer
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Lungpacer
3 dated milestones of Lungpacer across 17 years, from founding to its latest funding, stage changes and deals.
- Founded Lungpacer is founded.
- Funding First funding round of $156K.
- Funding Latest funding round, Series B,.
Competitors of Lungpacer
Lungpacer operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Belluscura, hemovent, ALung, OneBreath and Securisyn, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| belluscura.com | 2015 | Dallas, United States | $6.38M | 21 | Provider of medical devices for laparoscopic procedures | |
| hemovent.com | 2013 | Aachen, Germany | $16.7M | 23 | Equipment for extracorporeal life support and CO2 removal is developed. | |
| alung.com | 1997 | Pittsburgh, United States | $132.56M | 27 | Extracorporeal CO2 removal systems are developed to supplement mechanical ventilation. | |
| onebreathventilators.com | 2013 | Bengaluru, India | $3.45M | 26 | Portable mechanical ventilators for intensive care patients are developed. | |
| securisyn.com | 2011 | Denver, United States | $16.79M | – | Endotracheal tube stabilization systems for ventilated patients are developed. | |
| breethe.com | 2014 | Montreal, Canada | – | – | Meditation programs are delivered through a mobile app by Breethe. | |
| briodevice.com | 2010 | Doylestown, United States | $1.94M | – | Medical devices for emergency airway management are developed. |
Detailed competitors of Lungpacer
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Lungpacer
The website of Lungpacer (lungpacer.com) receives about 1.4K visits a month.
- Monthly visits1.4K
▲ 73.7% vs previous month
Latest news on Lungpacer
Complete news archive for Lungpacer
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Lungpacer
10 companies that operate in the same segment as Lungpacer (Pulmonology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Portable oxygen concentrators are supplied for respiratory therapy needs. | 2001 | Goleta, California, United States | USD 51.65 M | USD 348.67 M | 766 | |
Cancer detection diagnostics assays are developed and offered. | 2005 | Boulder, Colorado, United States | USD 200.16 M | USD 88.5 M | 273 | |
Therapeutic devices for nasal breathing improvement are developed. | 2011 | Sunnyvale, California, United States | USD 176.4 M | – | 66 | |
Non-invasive breath-based diagnostics for cancer and infectious diseases are developed. | 2004 | Cambridge, Cambridgeshire, United Kingdom | USD 166.55 M | – | 202 | |
Protein biologics are developed for treating rare diseases. | 2005 | San Diego, California, United States | USD 171.52 M | USD 190 K | 59 | |
Therapeutics for rare respiratory diseases are developed by Savara Pharma. | 2008 | Austin, Texas, United States | USD 67.82 M | – | 59 | |
Developer of smart devices for treating pulmonary diseases | 1998 | Redwood City, California, United States | USD 280.91 M | USD 90.5 M | 291 | |
A norovirus vaccine is developed for infection prevention. | 2021 | Boston, Massachusetts, United States | USD 135 M | – | 14 | |
Oral small molecule drugs for chronic diseases are developed. | 2017 | San Francisco, California, United States | USD 233 M | – | 163 | |
Precision medicines for lung-related diseases are developed. | 2015 | Menlo Park, California, United States | USD 371 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Lungpacer
Lungpacer was founded in 2009 and raised its 1st funding round 4 years after it was founded.
Lungpacer is headquartered in Vancouver, Canada. It is registered at Vancouver, British Columbia, Canada.
Doug Evans is the current CEO of Lungpacer.
Lungpacer is a funded company, having raised a total of $121.38M across 8 funding rounds to date. The company's 1st funding round was a Grant of $155.85K, raised on Mar 2013.
Lungpacer was founded in 2009 in Vancouver, Canada, within the medical device sector focused on respiratory health. A neurostimulation system is provided by the company, utilizing minimally invasive transvascular technology to activate the diaphragm. Electrodes are inserted intravenously to enable rhythmic stimulation, restoring negative pressure ventilation. Pacing therapy is applied to prevent or reverse diaphragm muscle atrophy and sustain endurance. Operations center on this technology for clinical applications.
Lungpacer's top competitors include Belluscura, hemovent and ALung.
Lungpacer offers AeroPace System and AeroNova System.
Lungpacer has 2 investors. Key investors include Canadian Institutes of Health Research, and Military Health.
Lungpacer operates through Lungpacer Medical, Inc..